It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine, which was co ...

The mRNA-1083 generated an equivalent or better immunological response compared to current flu vaccines, matching GSK’s Fluarix Quadrivalent in adults aged 50 to 64 and outperforming Sanofi’s ...

Fluarix Tetra (GSK) is no longer marketed, while there is no stock of SKYCellflu (Pharmaniaga Marketing, SK Bioscience Korea) in the country, he added. “Currently, there is an unexpected surge ...

Fluarix™, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to assess the non-inferiority of HI antibody responses ...

“Fluarix Tetra (GSK) is no longer marketed, and SKYCellflu (Pharmaniaga Marketing, SK Bioscience Korea) has no stock in the country. “Currently, there is an unexpected surge in demand for ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine co-developed in ...